Open AccessMonthly Oral Ibandronate Is Well Tolerated and Efficacious in Postmenopausal Women: Results from the Monthly Oral Pilot Study
Author(s) -
JeanYves Reginster,
Katie Wilson,
Étienne Dumont,
Bernard Bonvoisin,
Joanne Barrett
Publication year - 2005
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2004-1750
Subject(s) - medicine , postmenopausal women
Ibandronate, a potent, nitrogen-containing bisphosphonate developed for intermittent administration in postmenopausal osteoporosis, aims to overcome current adherence issues with daily and weekly oral bisphosphonates through once-monthly oral dosing.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom